Chief Development Officer

Thomas P. Monath, MD

Tom was previously the Managing Partner and Chief Scientist of Crozet BioPharma LLC, a biopharmaceutical company working on vaccines against Marburg and Nipah viruses with funding from BARDA and CEPI. He was formerly CSO and COO of the ID Division of NewLink Genetics, where he led development of the most advanced Ebola virus vaccine in partnership with Merck. Tom has over 25 years’ experience in the biotechnology industry, including as CSO and Executive Director of Acambis prior to its acquisition by Sanofi Pasteur, where he directed R&D on vaccines against dengue, Japanese encephalitis, West Nile, yellow fever, Clostridium difficile, and smallpox, three of which are now licensed products. From 2006-2012 Tom was a partner at Kleiner, Perkins Caufield & Byers, a preeminent venture capital firm. He was Director, Division of Vector-Borne Viral Diseases at the CDC (Ft Collins) and Chief, Virology Division at USAMRIID. He served on numerous WHO expert committees and the National Vaccines Advisory Committee. He is Past-President of the American Society of Tropical Medicine & Hygiene and has published over 450 papers and 6 books on virology and vaccine development.